It is also likely that DDX3X inhibitors would be more effective in combination with other established lymphoma drugs such as cyclophosphamide, etoposide, doxorubicine and others, allowing to reduce their dosage and thereby overall toxicity and enhancing their effectiveness. The gene discussed is DDX3X; the disease is lymphoma.